• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe, it’s free!
  • Search
  • Menu Menu
Clinical Laboratory int.

Archive for category: E-News

E-News

Arctoris appoints three experienced industry executives to Advisory Board

, 27 January 2021/in E-News /by 3wmedia

Arctoris, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts as members of its Advisory Board: Beth J Hoffman PhD, Prof. Khusru Asadullah MD, and Stanley Lapidus.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/1_E-NEWS_ARCTORIS.jpg 474 1000 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:20:162021-01-29 01:22:40Arctoris appoints three experienced industry executives to Advisory Board

Carina Biotech to create cancer-busting CAR-T cells using Bionomics antibody

, 27 January 2021/in E-News /by 3wmedia

In an exclusive agreement with Bionomics Limited, Australia’s Carina Biotech will create Chimeric Antigen Receptor T cells (CAR-T cells) and other adoptive cell therapies to the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) using the first-in-class humanised antibody BNC101 developed by Bionomics.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:17:362021-01-29 01:22:40Carina Biotech to create cancer-busting CAR-T cells using Bionomics antibody

BioMedion buys compliance division of arivis

, 27 January 2021/in E-News /by 3wmedia

BioMedion, a global Compliance Management Software company providing controlled content and raw data management solutions for the life science industry, has acquired the Compliance Division of arivis, a provider of regulatory software and biomedical 3D and big image data software solutions.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:16:212021-01-29 01:22:41BioMedion buys compliance division of arivis

Nordic Capital, Astorg jointly acquire Cytel

, 27 January 2021/in E-News /by 3wmedia

Nordic Capital and Astorg have jointly acquired acquire Cytel Inc. from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:15:102021-01-29 01:22:41Nordic Capital, Astorg jointly acquire Cytel

LSBio acquires Absolute Antibody

, 27 January 2021/in E-News /by 3wmedia

Seattle, US-based LSBio, a leading provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody and its sister company Kerafast. Terms of the transaction were not disclosed.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/2_E-NEWS_LSBIO.jpg 521 690 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:13:192021-01-29 01:22:41LSBio acquires Absolute Antibody

European Commission’s Open Research Europe platform up and running

, 27 January 2021/in E-News /by 3wmedia

The new Open Research Europe (ORE) platform – funded by the European Commission – is now up and running.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:12:012021-01-29 01:22:42European Commission’s Open Research Europe platform up and running

Ovarian cancer project shows promise

, 27 January 2021/in E-News /by 3wmedia

Due to promising results, Porvair Sciences has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/3_E-NEWS_OVARIAN.jpg 575 1000 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:10:082021-01-29 01:22:42Ovarian cancer project shows promise

Mogrify secures IP foundational to its cell conversion technology

, 27 January 2021/in E-News /by 3wmedia

UK-based Mogrify has secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (Mogrify V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (Mogrify V2). The expansion of rights allows the Company to bring the latest version […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/4_E-NEWS_MOGRIFY.jpg 995 676 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:06:382021-01-29 01:22:42Mogrify secures IP foundational to its cell conversion technology

Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test

, 27 January 2021/in E-News /by 3wmedia

Novigenix SA Switzerland, a pioneer in immuno-transcriptomics for precision medicine, will lead a consortium, including PamGene International and Radboud University (The Netherlands), to develop a blood based multi-omics test to predict response to immune checkpoint inhibitors in cancer. The consortium has been awarded a grant up to €1 million under the Eurostars programme.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:04:492021-01-29 01:22:43Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test

Pepscope secures investment to boost development kinase inhibitor therapies

, 27 January 2021/in E-News /by 3wmedia

Dutch biotech company Pepscope, offering endogenous protein kinase activity profiling technologies, has secured €4.3 million funding to further develop and commercialize their lead product QuantaKinome.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/5_E-NEWS_PEPSCOPE.jpg 415 675 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2021-01-27 01:03:332021-01-29 01:22:43Pepscope secures investment to boost development kinase inhibitor therapies
Page 1 of 155123›»

Latest issue of Clinical laboratory

December 2020 / January 2021

2 March 2021

KLoneus® Free Light Chain (FLC) assays, for Turdidimetry and Nephelometry

2 March 2021

Optimised Microplates for Affinity Binding Assays

16 February 2021

Greiner Bio-One introduces VACUETTE FC Mix Tube for effective glycolysis inhibition

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release

Parklaan 54a
5613 BH
Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only